"Taken together the interplay of sex-specific gene regulation and its impact on ECM-related genes, influenced by factors such as genetics, epigenetics, environmental exposures, steroid hormones, aging ...
Mepolizumab targets IL-5, addressing eosinophilic inflammation in 20%-40% of COPD patients, marking its fifth US indication. The phase 3 MATINEE trial showed a 21% reduction in annualized moderate or ...
Researchers conducted a retrospective cohort study using data from the Clinical Practice Research Datalink Aurum database between January 1, 2010, and December 31, 2019, to analyse patients with COPD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results